Redirecting the immune response: Role of adoptive T cell therapy

Human Gene Therapy

Volumn 21, Issue 5, 2010, Pages 533-541

  Mondino, Anna ^a   Dardalhon, Valérie ^b   Michelini, Rodrigo Hess ^a   Loisel Meyer, Severine ^b   Taylor, Naomi ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CANCER VACCINE; CD4 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GEMCITABINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; LENTIVIRUS VECTOR; MELPHALAN; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 7; RETROVIRUS VECTOR; TREOSULFAN;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EFFECTOR CELL; EX VIVO GENE TRANSFER; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MELANOMA; MEMORY T LYMPHOCYTE; MYELOABLATIVE CONDITIONING; NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; WHOLE BODY RADIATION;

ANIMALS; HUMANS; IMMUNE SYSTEM PROCESSES; LYMPHOCYTES; NEOPLASMS; T-LYMPHOCYTES; TISSUE THERAPY;

EID: 77951967198     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.033     Document Type: Review

References (102)

1. Abad, J.D., Wrzensinski, C., Overwijk, W., De Witte, M.A., Jorritsma, A., Hsu, C., Gattinoni, L., Cohen, C.J., Paulos, C.M., Palmer, D.C., Haanen, J.B., Schumacher, T.N., Rosenberg, S.A., Restifo, N.P., and Morgan, R.A. (2008). T-cell receptor gene therapy of established tumors in a murine melanoma model. J. Immunother. 31, 1-6.
2. \+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174, 2591-2601.
3. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F.J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J.P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., Andre, F., Delaloge, S., Tursz, T., Kroemer, G., and Zitvogel, L. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050-1059.
4. Benigni, F., Zimmermann, V.S., Hugues, S., Caserta, S., Basso, V., Rivino, L., Ingulli, E., Malherbe, L., Glaichenhaus, N., and Mondino, A. (2005). Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. J. Immunol. 175, 739-748.
5. \+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305.
6. Berger, C., Berger, M., Hackman, R.C., Gough, M., Elliott, C., Jensen, M.C., and Riddell, S.R. (2009). Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114, 2417-2426.
7. Berry, L.J., Moeller, M., and Darcy, P.K. (2009). Adoptive immu-notherapy for cancer: The next generation of gene-engineered immune cells. Tissue Antigens 74, 277-289.
8. Bolotin, E., Annett, G., Parkman, R., and Weinberg, K. (1999). Serum levels of IL-7 in bone marrow transplant recipients: Relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 23, 783-788.
9. Bracci, L., Moschella, F., Sestili, P., La Sorsa, V., Valentini, M., Canini, I., Baccarini, S., Maccari, S., Ramoni, C., Belardelli, F., and Proietti, E. (2007). Cyclophosphamide enhances the anti-tumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell ho-meostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13, 644-653.
10. Broomfield, S., Currie, A., van der Most, R.G., Brown, M., van Bruggen, I., Robinson, B.W., and Lake, R.A. (2005). Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 65, 7580-7584.
11. Butcher, E.C., and Picker, L.J. (1996). Lymphocyte homing and homeostasis. Science 272, 60-66.
12. Calzascia, T., Pellegrini, M., Lin, A., Garza, K.M., Elford, A.R., Shahinian, A., Ohashi, P.S., and Mak, T.W. (2008). CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoim-munity. Proc. Natl. Acad. Sci. U.S.A. 105, 2999-3004.
13. Capitini, C.M., Chisti, A.A., and Mackall, C.L. (2009). Modulating T-cell homeostasis with IL-7: Preclinical and clinical studies. J. Intern. Med. 266, 141-153.
14. Casati, A., Zimmermann, V.S., Benigni, F., Bertilaccio, M.T., Bellone, M., and Mondino, A. (2005). The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration. J. Immunol. 174, 3317-3325.
15. \+ T cells. Eur. J. Immunol. 40, 470-479.
16. Cavalieri, S., Cazzaniga, S., Geuna, M., Magnani, Z., Bordignon, C., Naldini, L., and Bonini, C. (2003). Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102, 497-505.
17. Cheadle, E.J., Gilham, D.E., and Hawkins, R.E. (2008). The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br. J. Haematol. 142, 65-68.
18. Circosta, P., Granziero, L., Follenzi, A., Vigna, E., Stella, S., Vallario, A., Elia, A.R., Gammaitoni, L., Vitaggio, K., Orso, F., Geuna, M., Sangiolo, D., Todorovic, M., Giachino, C., and Cignetti, A. (2009). T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum. Gene Ther. 20, 1576-1588.
19. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mot-tram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M.L., Knutson, K.L., Chen, L., and Zou, W. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949.
20. \+ T cells. Proc. Natl. Acad. Sci. U.S.A. 98, 9277-9282.
21. hi memory Tregs that create a dominant tolero-genic environment for tumors in mice. J. Clin. Invest. 119, 2648-2662.
22. \+ T cells in ex vivo generated, antil-eukemia human cytotoxic T lymphocyte lines. J. Immunother. 31, 385-393.
23. Davis, I.D., Brady, B., Kefford, R.F., Millward, M., Cebon, J., Skrumsager, B.K., Mouritzen, U., Hansen, L.T., Skak, K., Lundsgaard, D., Frederiksen, K.S., Kristjansen, P.E., and McArthur, G. (2009). Clinical and biological efficacy of re-combinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: A phase IIa trial. Clin. Cancer Res. 15, 2123-2129.
24. de Witte, M.A., Jorritsma, A., Kaiser, A., van den Boom, M.D., Dokter, M., Bendle, G.M., Haanen, J.B., and Schumacher, T.N. (2008). Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol. 181, 5128-5136.
25. Di Stasi, A., De Angelis, B., Rooney, C.M., Zhang, L., Mahen-dravada, A., Foster, A.E., Heslop, H.E., Brenner, M.K., Dotti, G., and Savoldo, B. (2009). T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392-6402.
26. Dotti, G., Savoldo, B., and Brenner, M. (2009). Fifteen years of gene therapy based on chimeric antigen receptors: "Are we nearly there yet?" Hum. Gene Ther. 20, 1229-1239.
27. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A., Rogers, L.J., Gracia, G.J., Jones, S.A., Mangiameli, D.P., Pelletier, M.M., Gea-Banacloche, J., Robinson, M.R., Berman, D.M., Filie, A.C., Abati, A., and Rosenberg, S.A. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357.
28. Frumento, G., Piazza, T., Di Carlo, E., and Ferrini, S. (2006). Targeting tumor-related immunosuppression for cancer im-munotherapy. Endocr. Metab. Immune Disord. Drug Targets 6, 233-237.
29. Fry, T.J., Connick, E., Falloon, J., Lederman, M.M., Liewehr, D.J., Spritzler, J., Steinberg, S.M., Wood, L.V., Yarchoan, R., Zuck-erman, J., Landay, A., and Mackall, C.L. (2001). A potential role for interleukin-7 in T-cell homeostasis. Blood 97, 2983-2990.
30. Ganss, R., Ryschich, E., Klar, E., Arnold, B., and Hammerling, G.J. (2002). Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62, 1462-1470.
31. \+ T cells. J. Exp. Med. 202, 907-912.
32. Gattinoni, L., Powell, D.J., Jr., Rosenberg, S.A., and Restifo, N.P. (2006). Adoptive immunotherapy for cancer: Building on success. Nat. Rev. Immunol. 6, 383-393.
33. \+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344.
34. Gilham, D.E., Lie, A.L.M., Taylor, N., and Hawkins, R.E. (2010). Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors. J. Gene Med. 12, 129-136.
35. \+ T cells in lym-phopenic hosts. Immunity 11, 183-190.
36. \+ T cells. Nat. Immunol. 10, 149-157.
37. Hadrup, S.R., Bakker, A.H., Shu, C.J., Andersen, R.S., van Veluw, J., Hombrink, P., Castermans, E., Thor Straten, P., Blank, C., Haanen, J.B., Heemskerk, M.H., and Schumacher, T.N. (2009). Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520-526.
38. \+ T cells. Proc. Natl. Acad. Sci. U.S.A. 105, 18484-18489.
39. Hess Michelini, R., Freschi, M., Manzo, T., Jachetti, E., Degl'in-nocenti, E., Grioni, M., Basso, V., Bonini, C., Simpson, E., Mondino, A., and Bellone, M. (2010). Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res. (in press).
40. \+ T cells for adoptive immunotherapy. Blood 111, 5326-5333.
41. \+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 106, 17469-17474.
42. Hirschhorn-Cymerman, D., Rizzuto, G.A., Merghoub, T., Cohen, A.D., Avogadri, F., Lesokhin, A.M., Weinberg, A.D., Wolchok, J.D., and Houghton, A.N. (2009). OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 206, 1103-1116.
43. Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A., Macrae, S., Nelson, M., Canning, C., Lowy, I., Korman, A., Lautz, D., Russell, S., Jaklitsch, M.T., Ramaiya, N., Chen, T.C., Neuberg, D., Allison, J.P., Mihm, M.C., and Dranoff, G. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U.S.A. 105, 3005-3010.
44. Huarte, E., Fisher, J., Turk, M.J., Mellinger, D., Foster, C., Wolf, B., Meehan, K.R., Fadul, C.E., and Ernstoff, M.S. (2009). Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett. 285, 80-88.
45. \+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis. J. Immunol. 171, 61-68.
46. Jiang, H.R., Gilham, D.E., Mulryan, K., Kirillova, N., Hawkins, R.E., and Stern, P.L. (2006). Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J. Immunol. 177, 4288-4298.
47. Kaka, A.S., Shaffer, D.R., Hartmaier, R., Leen, A.M., Lu, A., Bear, A., Rooney, C.M., and Foster, A.E. (2009). Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cyto-toxic T-lymphocytes. J. Immunother. 32, 726-736.
48. \+ T cells favors terminal-effector differentiation in vivo. Immunity 32, 91-103.
49. Kammertoens, T., and Blankenstein, T. (2009). Making and circumventing tolerance to cancer. Eur. J. Immunol. 39, 2345-2353.
50. Kaneko, S., Mastaglio, S., Bondanza, A., Ponzoni, M., Sanvito, F., Aldrighetti, L., Radrizzani, M., La Seta-Catamancio, S., Provasi, E., Mondino, A., Nagasawa, T., Fleischhauer, K., Russo, V., Traversari, C., Ciceri, F., Bordignon, C., and Bonini, C. (2009). IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113, 1006-1015.
51. Kershaw, M.H., Wang, G., Westwood, J.A., Pachynski, R.K., Tiffany, H.L., Marincola, F.M., Wang, E., Young, H.A., Murphy, P.M., and Hwu, P. (2002). Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13, 1971-1980.
52. Kieper, W.C., Troy, A., Burghardt, J.T., Ramsey, C., Lee, J.Y., Jiang, H.Q., Dummer, W., Shen, H., Cebra, J.J., and Surh, C.D. (2005). Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J. Immunol. 174, 3158-3163.
53. King, J.W., Thomas, S., Corsi, F., Gao, L., Dina, R., Gillmore, R., Pigott, K., Kaisary, A., Stauss, H.J., and Waxman, J. (2009). IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer. Clin. Cancer Res. 15, 1145-1154.
54. \+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U.S.A. 102, 9571-9576.
55. Kohlmeyer, J., Cron, M., Landsberg, J., Bald, T., Renn, M., Mikus, S., Bondong, S., Wikasari, D., Gaffal, E., Hartmann, G., and Tuting, T. (2009). Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 69, 6265-6274.
56. Koike, N., Pilon-Thomas, S., and Mule, J.J. (2008). Non-myeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J. Immunother. 31, 402-412.
57. Laurencot, C.M., and Ruppel, S. (2009). Regulatory aspects for translating gene therapy research into the clinic. Methods Mol. Biol. 542, 397-421.
58. \+ T cells cooperate to break peripheral tolerance under lymphopenic conditions. Proc. Natl. Acad. Sci. U.S.A. 105, 19414-19419.
59. Liu, S., Riley, J., Rosenberg, S., and Parkhurst, M. (2006). Comparison of common g-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 29, 284-293.
60. Miyagawa, F., Tagaya, Y., Kim, B.S., Patel, H.J., Ishida, K., Ohteki, T., Waldmann, T.A., and Katz, S.I. (2008). IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease. J. Immunol. 181, 1109-1119.
61. \+ helper T cells induces potent primary and secondary tumor rejection. Blood 106, 2995-3003.
62. Muranski, P., Boni, A., Wrzesinski, C., Citrin, D.E., Rosenberg, S.A., Childs, R., and Restifo, N.P. (2006). Increased intensity lymphodepletion and adoptive immunotherapy: How far can we go? Nat. Clin. Pract. Oncol. 3, 668-681.
63. Nakayama, M., Itoh, K., and Takahashi, E. (1997). Cyclophos-phamide- induced bacterial translocation in Escherichia coli C25-monoassociated specific pathogen-free mice. Microbiol. Immunol. 41, 587-593.
64. Nistico, P., Capone, I., Palermo, B., Del Bello, D., Ferraresi, V., Moschella, F., Arico, E., Valentini, M., Bracci, L., Cognetti, F., Ciccarese, M., Vercillo, G., Roselli, M., Fossile, E., Tosti, M.E., Wang, E., Marincola, F., Imberti, L., Catricala, C., Natali, P.G., Belardelli, F., and Proietti, E. (2009). Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer 124, 130-139.
65. Nowak, A.K., Robinson, B.W., and Lake, R.A. (2003). Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63, 4490-4496.
66. Ostrand-Rosenberg, S., and Sinha, P. (2009). Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 182, 4499-4506.
67. \+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594.
68. \+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197-2204.
69. Pellegrini, M., Calzascia, T., Elford, A.R., Shahinian, A., Lin, A.E., Dissanayake, D., Dhanji, S., Nguyen, L.T., Gronski, M.A., Morre, M., Assouline, B., Lahl, K., Sparwasser, T., Ohashi, P.S., and Mak, T.W. (2009). Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance im-munotherapies. Nat. Med. 15, 528-536.
70. Petrausch, U., Poehlein, C.H., Jensen, S.M., Twitty, C., Thompson, J.A., Assmann, I., Puri, S., Lacelle, M.G., Moudgil, T., Maston, L., Friedman, K., Church, S., Cardenas, E., Haley, D.P., Walker, E.B., Akporiaye, E., Weinberg, A.D., Rosenheim, S., Crocenzi, T.S., Hu, H.M., Curti, B.D., Urba, W.J., and Fox, B.A. (2009). Cancer immunotherapy: The role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr. Mol. Med. 9, 673-682.
71. Pilla, L., Rivoltini, L., Patuzzo, R., Marrari, A., Valdagni, R., and Parmiani, G. (2009). Multipeptide vaccination in cancer patients. Expert Opin. Biol. Ther. 9, 1043-1055.
72. Pipkin, M.E., Sacks, J.A., Cruz-Guilloty, F., Lichtenheld, M.G., Bevan, M.J., and Rao, A. (2010). Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32, 79-90.
73. Polak, L., and Turk, J.L. (1974). Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249, 654-656.
74. Pouw, N., Treffers-Westerlaken, E., Mondino, A., Lamers, C., and Debets, R. (2010) TCR gene-engineered T cell: Limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol. Immunol. 2010 Mar 17. [Epub ahead of print].
75. Powell, D.J., Jr., and Levine, B.L. (2008). Adoptive T-cell therapy for malignant disorders. Haematologica 93, 1452-1456.
76. \+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637-650.
77. Ribas, A., Comin-Anduix, B., Chmielowski, B., Jalil, J., De La Rocha, P., McCannel, T.A., Ochoa, M.T., Seja, E., Villanueva, A., Oseguera, D.K., Straatsma, B.R., Cochran, A.J., Glaspy, J.A., Hui, L., Marincola, F.M., Wang, E., Economou, J.S., and Gomez-Navarro, J. (2009). Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15, 6267-6276.
78. \+ T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 206, 849-866.
79. Rosenberg, S.A. (2001). Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
80. Saini, M., Pearson, C., and Seddon, B. (2009). Regulation of T cell-dendritic cell interactions by IL-7 governs T-cell activation and homeostasis. Blood 113, 5793-5800.
81. \+ T-cell response to peptide vaccination: Creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30, 40-53.
82. Salem, M.L., Diaz-Montero, C.M., Al-Khami, A.A., El-Naggar, S.A., Naga, O., Montero, A.J., Khafagy, A., and Cole, D.J. (2009). Recovery from cyclophosphamide-induced lympho-penia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J. Immunol. 182, 2030-2040.
83. Salem, M.L., Al-Khami, A.A., El-Naggar, S.A., Diaz-Montero, C.M., Chen, Y., and Cole, D.J. (2010). Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J. Immunol. 184, 1737-1747.
84. \+ memory T cells: Functional modules for tailored immunity. Eur. J. Immunol. 39, 2076-2082.
85. Schluns, K.S., Kieper, W.C., Jameson, S.C., and Lefrancois, L. (2000). Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1, 426-432.
86. Schmitt, T.M., Ragnarsson, G.B., and Greenberg, P.D. (2009). T cell receptorgene therapy for cancer. Hum. Gene Ther. 20, 1240-1248.
87. Schumacher, T.N., and Restifo, N.P. (2009). Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 21, 187-189.
88. Seddon, B., and Zamoyska, R. (2002a). TCR and IL-7 receptor signals can operate independently or synergize to promote lymphopenia-induced expansion of naive T cells. J. Immunol. 169, 3752-3759.
89. Seddon, B., and Zamoyska, R. (2002b). TCR signals mediated by Src family kinases are essential for the survival of naive T cells. J. Immunol. 169, 2997-3005.
90. Sportes, C., Gress, R.E., and Mackall, C.L. (2009). Perspective on potential clinical applications of recombinant human interleukin-7. Ann. N.Y. Acad. Sci. 1182, 28-38.
91. Sportes, C., Babb, R.R., Krumlauf, M.C., Hakim, F.T., Steinberg, S.M., Chow, C.K., Brown, M.R., Fleisher, T.A., Noel, P., Maric, I., Stetler-Stevenson, M., Engel, J., Buffet, R., Morre, M., Amato, R.J., Pecora, A., Mackall, C.L., and Gress, R.E. (2010). Phase I study of recombinant human interleukin-7 administrationinsubjects with refractory malignancy. Clin. Cancer Res. 16, 727-735.
92. Surh, C.D., and Sprent, J. (2000). Homeostatic T cell proliferation: How far can T cells be activated to self-ligands? J. Exp. Med. 192, F9-F14.
93. Teitz-Tennenbaum, S., Li, Q., Davis, M.A., Wilder-Romans, K., Hoff, J., Li, M., and Chang, A.E. (2009). Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J. Immun-other. 32, 602-612.
94. Thistlethwaite, F.C., Elkord, E., Griffiths, R.W., Burt, D.J., Shablak, A.M., Campbell, J.D., Gilham, D.E., Austin, E.B., Stern, P.L., and Hawkins, R.E. (2008). Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol. Immunother. 57, 623-634.
95. Thompson, J.A., Curti, B.D., Redman, B.G., Bhatia, S., Weber, J.S., Agarwala, S.S., Sievers, E.L., Hughes, S.D., Devries, T.A., and Hausman, D.F. (2008). Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 26, 2034-2039.
96. Verdeil, G., Marquardt, K., Surh, C.D., and Sherman, L.A. (2008). Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 105, 16683-16688.
97. Verhoeyen, E., Dardalhon, V., Ducrey-Rundquist, O., Trono, D., Taylor, N., and Cosset, F.L. (2003). IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 101, 2167-2174.
98. Vierboom, M.P., Bos, G.M., Ooms, M., Offringa, R., and Melief, C.J. (2000). Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int. J. Cancer 87, 253-260.
99. Vogt, T.K., Link, A., Perrin, J., Finke, D., and Luther, S.A. (2009). Novel function for interleukin-7 in dendritic cell development. Blood 113, 3961-3968.
100. Walker, R.E., Bechtel, C.M., Natarajan, V., Baseler, M., Hege, K.M., Metcalf, J.A., Stevens, R., Hazen, A., Blaese, R.M., Chen, C.C., Leitman, S.F., Palensky, J., Wittes, J., Davey, R.T., Jr., Falloon, J., Polis, M.A., Kovacs, J.A., Broad, D.F., Levine, B.L., Roberts, M.R., Masur, H., and Lane, H.C. (2000). Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96, 467-474.
101. Xue, S.A., and Stauss, H.J. (2007). Enhancing immune responses for cancer therapy. Cell. Mol. Immunol. 4, 173-184.
102. Zhang, B., Bowerman, N.A., Salama, J.K., Schmidt, H., Spiotto, M.T., Schietinger, A., Yu, P., Fu, Y.X., Weichselbaum, R.R., Rowley, D.A., Kranz, D.M., and Schreiber, H. (2007). Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204, 49-55.